ATE220100T1 - Mit gp11b/iiia reaktive humane antikörper - Google Patents

Mit gp11b/iiia reaktive humane antikörper

Info

Publication number
ATE220100T1
ATE220100T1 AT92924918T AT92924918T ATE220100T1 AT E220100 T1 ATE220100 T1 AT E220100T1 AT 92924918 T AT92924918 T AT 92924918T AT 92924918 T AT92924918 T AT 92924918T AT E220100 T1 ATE220100 T1 AT E220100T1
Authority
AT
Austria
Prior art keywords
iiia
gp11b
human antibodies
antibodies reactive
gpiib
Prior art date
Application number
AT92924918T
Other languages
English (en)
Inventor
Man Sung Co
Yun J Tso
Original Assignee
Yamanouchi Pharma Co Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd, Protein Design Labs Inc filed Critical Yamanouchi Pharma Co Ltd
Application granted granted Critical
Publication of ATE220100T1 publication Critical patent/ATE220100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92924918T 1991-12-20 1992-12-15 Mit gp11b/iiia reaktive humane antikörper ATE220100T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211191A 1991-12-20 1991-12-20
US89595292A 1992-06-09 1992-06-09
US94415992A 1992-09-11 1992-09-11
PCT/JP1992/001630 WO1993013133A1 (en) 1991-12-20 1992-12-15 HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa

Publications (1)

Publication Number Publication Date
ATE220100T1 true ATE220100T1 (de) 2002-07-15

Family

ID=27420074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924918T ATE220100T1 (de) 1991-12-20 1992-12-15 Mit gp11b/iiia reaktive humane antikörper

Country Status (10)

Country Link
EP (1) EP0619324B1 (de)
JP (1) JP2723671B2 (de)
KR (1) KR100240159B1 (de)
AT (1) ATE220100T1 (de)
AU (1) AU3095892A (de)
CA (1) CA2126182C (de)
DE (1) DE69232669T2 (de)
ES (1) ES2179824T3 (de)
MX (1) MX9207459A (de)
WO (1) WO1993013133A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676965B1 (de) * 1992-11-16 2007-07-25 Centocor Inc. Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern
PT725655E (pt) * 1993-11-05 2004-01-30 Centocor Inc Utilizacao de compostos capazes de se ligar a glicoproteina gpiib/iiia para a prevencao de estenose e de restenose
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
TR199902800T2 (xx) 1997-05-15 2000-04-21 Chugai Seiyaku Kabushiki Kaisha Ka�eksiyi tedavi edici madde.
EP0990034A1 (de) 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
EP1174148A4 (de) * 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd Parenterale medizinische zusammensetzungen enthaltend fragmente humanisierter monoklonaler antikörper und methode zur stabilisierung derselben
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
ATE420661T1 (de) 2000-04-28 2009-01-15 Chugai Pharmaceutical Co Ltd Zellproliferation-inhibitoren
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.

Also Published As

Publication number Publication date
CA2126182C (en) 2001-07-17
CA2126182A1 (en) 1993-07-08
EP0619324A4 (en) 1995-11-29
DE69232669D1 (de) 2002-08-08
ES2179824T3 (es) 2003-02-01
KR940703859A (ko) 1994-12-12
MX9207459A (es) 1994-03-31
EP0619324A1 (de) 1994-10-12
JP2723671B2 (ja) 1998-03-09
AU3095892A (en) 1993-07-28
WO1993013133A1 (en) 1993-07-08
DE69232669T2 (de) 2003-02-27
EP0619324B1 (de) 2002-07-03
KR100240159B1 (ko) 2000-01-15

Similar Documents

Publication Publication Date Title
DE69133476D1 (de) Transgene Mäuse fähig zur Produktion heterologer Antikörper
ATE81153T1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE69232669D1 (de) Mit gp11b/iiia reaktive humane antikörper
DK0652962T3 (da) Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
DK0502812T3 (da) Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DK564989D0 (da) Bindingsproteiner
ATE167896T1 (de) Aus mehreren domänen bestehende hämatopoese- stimulatoren
FI944509A0 (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
ATE133200T1 (de) Modifiziertes, biologisch aktives protein
DK0407813T3 (da) Oxidativ denaturering af proteinanalytter
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
NO175639C (no) Peptid, antistoff oppnådd ved hjelp av peptidet, en fremgangsmåte for immunologisk bestemmelse av intakt prokollagen peptid (type III) og anvendelse av peptidet
DK442888A (da) Slaegtspecifikt listeria-antigen identificeret ved hjaelp af monoklone antistoffer
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
DK329789A (da) Monoklonalt antistof
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties